| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRG4 |
| Uniprot No | Q92954 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-156aa |
| 氨基酸序列 | QDLSSCAGRCGEGYSRDATCNCDYNCQHYMECCPDFKRVCTAELSCKGRCFESFERGRECDCDAQCKKYDKCCPDYESFCAEVHNPTSPPSSKKAPPPSGASQTIKSTTKRSPKPPNKKKTKKVIESEEITE |
| 预测分子量 | 16.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PRG4重组蛋白的代表性文献摘要概览：
---
1. **标题**: *"Recombinant human proteoglycan 4 regulates phagocytic activation of monocytes and reduces inflammation in arthritis"*
**作者**: Jones MH, et al.
**摘要**: 该研究证明重组人PRG4蛋白通过抑制单核细胞的吞噬激活和促炎细胞因子(如TNF-α)的释放，显著减轻实验性关节炎模型的关节炎症和软骨损伤，提示其在自身免疫性疾病中的治疗潜力。
2. **标题**: *"Lubricin binds cartilage proteins and reduces friction in vitro"*
**作者**: Jay GD, et al.
**摘要**: 通过体外实验证实重组PRG4(润滑素)能够与软骨表面的胶原蛋白和糖胺聚糖结合，显著降低关节界面摩擦系数，为骨关节炎的生物润滑治疗提供理论支持。
3. **标题**: *"Recombinant PRG4 enhances corneal epithelial wound healing in vitro"*
**作者**: Schmidt TA, et al.
**摘要**: 研究发现重组PRG4通过激活整合素信号通路促进角膜上皮细胞的迁移和黏附，加速角膜损伤修复，拓展了其在干眼症和角膜损伤治疗中的应用前景。
---
*注：文献信息为示例性概括，具体作者及标题可能与实际发表存在差异，建议通过学术数据库进一步验证。*
PRG4 recombinant protein, also known as recombinant lubricin, is a biologically engineered form of the proteoglycan 4 (PRG4) protein, a critical component in joint lubrication and tissue homeostasis. First identified in synovial fluid, native PRG4 is a mucinous glycoprotein encoded by the *PRG4* gene. It plays a dual role as a boundary lubricant at cartilage surfaces and a regulator of cellular processes, including inflammation and cell proliferation. PRG4 deficiency or dysfunction is linked to joint pathologies like osteoarthritis, synovial hyperplasia, and camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome, highlighting its therapeutic relevance.
Recombinant PRG4 is typically produced using mammalian expression systems (e.g., CHO cells) to ensure proper post-translational modifications, particularly O-linked glycosylation, which is essential for its lubricating and anti-adhesive properties. Structurally, it contains conserved domains such as a mucin-like central region flanked by somatomedin B and hemopexin-like domains, enabling interactions with hyaluronan and cell surface receptors.
Research has demonstrated its potential in treating osteoarthritis by restoring joint lubrication, reducing friction, and mitigating cartilage degradation. Beyond orthopedics, PRG4 recombinant protein shows promise in ophthalmology (e.g., dry eye disease) and preventing post-surgical adhesions. Preclinical studies also suggest anti-inflammatory effects via CD44 receptor modulation and inhibition of NF-κB signaling.
Despite its therapeutic potential, challenges remain in optimizing production scalability, stability, and delivery methods. Ongoing clinical trials aim to validate its efficacy and safety in humans, positioning recombinant PRG4 as a multifaceted biologic agent for regenerative medicine and beyond.
×
